Flagship's Digital Tissue Image Analysis Approach Validated in Assessment of Dystrophin Muscle Biopsies; Findings Published in Archives of Pathology & Laboratory Medicine

Westminster, CO, September 6, 2018 – Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual pathology. The study, “Validation of a Muscle-Specific Tissue Image-Analysis Tool for Quantitative Assessment of Dystrophin Staining in Frozen Muscle Biopsies,” was published in the Archives of […]

Read More

Flagship Secures Series A Funding to Accelerate Growth in Drug Development and Diagnostics Services

Westminster, CO, July 10, 2018 – Flagship Biosciences has closed a series A round of funding to advance the growth of its computational tissue image analysis technology platform and biomarker-driven drug development and diagnostic services. Since 2009, Flagship’s integrated team of scientists, pathologists, tissue and data analysts, and software engineers has worked with some of […]

Read More

Flagship publishes article on using IHC and digital imaging to improve patient selection for PD-L1 therapy

First NSCLC study using cTA to report IHC data in immuno-oncology Westminster, CO, June 7, 2018 – Flagship is proud to co-author the research paper, PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters, published June 6, 2018, in PLOS ONE, an open access peer-reviewed journal. The paper is the first Non-Small […]

Read More

Flagship Participates in ASCO Annual Meeting 2018

Download Flagship ASCO booth map Westminster, CO, May 23, 2018 – Flagship Biosciences will participate in the largest annual gathering of oncology professionals and researchers at the ASCO Annual Meeting 2018, June 1 – 5, 2018, in Chicago. Visit us in booth #25115 to learn how Flagship’s cTA® platform can help drive precision decisions for more […]

Read More

Flagship to Present Computational Tissue Analysis Solutions for Advancing Drug Development at AACR Annual Meeting

Download Flagship AACR reference Westminster, CO, April 12, 2018 – Flagship Biosciences’ cTA® and decision support platform will be featured in four scientific poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, April 14-18, 2018, in Chicago. As the leading partner for drug developers investigating tissue-based biomarkers, Flagship applies computational tissue analysis […]

Read More

Flagship Receives Accreditation from College of American Pathologists

Westminster, CO, April 10, 2018 – The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Flagship Biosciences, based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs. “CAP accreditation validates Flagship’s commitment and dedication to ensuring the highest quality for our clients and patients,” says […]

Read More

Flagship Biosciences ActionAnalysis Solutions Accelerate Drug Development

Ready-to-use and custom image analysis meets current and future development needs Westminster, CO, February 12, 2018 – Flagship Biosciences is adding to its menu of ready-to-use image solutions with the introduction of ActionAnalysisTM. As the most experienced, integrated clinical laboratory, Flagship’s ActionAnalysis solutions help drug developers rapidly evaluate existing targets to define a biomarker-driven path […]

Read More

Flagship supports Summit Therapeutics advancement of DMD therapies

January 26, 2018 – Flagship is proud to partner with Summit Therapeutics in its efforts to advance therapies for patients with Duchenne Muscular Dystrophy (DMD). Summit Therapeutics issued a news release disclosing the interim results from its DMD phase II clinical trial, PhaseOut DMD. The endpoints reported by Flagship for these efforts are the first […]

Read More

Flagship Biosciences ActionAssays Deliver Actionable Data to Drive Immuno-Oncology Decisions

Comprehensive catalog of assays advance biomarker programs Westminster, CO, January 16, 2018 – Flagship Biosciences has introduced a new menu of services to help drug developers more confidently define their path to success. ActionAssaysTM is a comprehensive catalog of brightfield immunohistochemistry (IHC) assays that provide actionable data to define and advance biomarker programs. ActionAssays includes […]

Read More

Flagship Biosciences Presents PD-L1 Scoring Method at SITC 2017 that could Eliminate Reliance on Complex Multiplex IHC Assays

Novel cTA™-based morphometric biomarker interpretation approach quantifies immune cells in tumor tissues and has potential to revolutionize PD-L1 diagnostics landscape National Harbor, MD – November 11th 2017 – Flagship Biosciences, Inc., the leading developer of quantitative tissue biomarker interpretations for clinical development of tissue-based diagnostics to drive clinical decisions for industry partners, presented data today […]

Read More